Clopidogrel Resistance and its effect on clinical outcomes in Acute Coronary Syndrome

Abstract

Clopidogrel resistance, influenced by CYP2C19 genetic polymorphisms, is a challenge for studying the clinical outcomes of individuals with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI). A total of 668 patients underwent genetic screening, and 143 had platelet function tests to study the association between drug metabolization and its effects based on platelet reactivity unit values. After 6 months of PCI, 54.64% of patients showed clopidogrel resistance with loss of function variation. Clinical outcomes, such as target vessel revascularization, target lesion revascularization, in-stent restenosis, and stent thrombosis, were also studied. This study highlights the association between gene polymorphism, clopidogrel resistance, and adverse clinical outcomes following PCI.